BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36618357)

  • 1. Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer.
    Zhou Z; Li J; Hong J; Chen S; Chen M; Wang L; Lin W; Ye Y
    Front Immunol; 2022; 13():1002361. PubMed ID: 36618357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
    Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
    Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
    Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
    Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model.
    Sasaki T; Sakoda Y; Adachi K; Tokunaga Y; Tamada K
    Cancer Med; 2023 Jun; 12(11):12569-12580. PubMed ID: 37031457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer.
    Ye J; Liu Q; He Y; Song Z; Lin B; Hu Z; Hu J; Ning Y; Cai C; Li Y
    J Transl Med; 2024 Feb; 22(1):171. PubMed ID: 38368374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
    Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Construction and functional analysis of EGFRvIII CAR-T cells co-expressing IL-15 and CCL19].
    Chen W; Xian N; Lin S; Liao W; Chen M
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3787-3799. PubMed ID: 37805854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical testing of CAR T cells in zebrafish xenografts.
    Grissenberger S; Salzer B; Pascoal S; Wenninger-Weinzierl A; Lehner M; Distel M
    Methods Cell Biol; 2022; 167():133-147. PubMed ID: 35152991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability.
    Hu JF; Wang ZW; Liao CY; Chen ZW; Kang FP; Lin CF; Lin TS; Huang L; Tian YF; Chen S
    Front Immunol; 2022; 13():958960. PubMed ID: 35990619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer.
    Murali Shankar N; Ortiz-Montero P; Kurzyukova A; Rackwitz W; Künzel SR; Wels WS; Tonn T; Knopf F; Eitler J
    Front Immunol; 2023; 14():1254821. PubMed ID: 37885894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of IL-4/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment.
    Zhou Y; Farooq MA; Ajmal I; He C; Gao Y; Guo D; Duan Y; Jiang W
    Biomed Pharmacother; 2023 Dec; 168():115740. PubMed ID: 37865999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma.
    Meng M; Wu YC
    J Immunol Res; 2021; 2021():1782728. PubMed ID: 34527749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
    Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
    PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
    Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.
    Chen C; Gu YM; Zhang F; Zhang ZC; Zhang YT; He YD; Wang L; Zhou N; Tang FT; Liu HJ; Li YM
    Oncoimmunology; 2021 Mar; 10(1):1901434. PubMed ID: 33854821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.